Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Transplants With Unlicensed Preserved Cord Blood

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 6, 2016 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ) Identifier:
First received: March 13, 2012
Last updated: May 12, 2017
Last verified: July 6, 2016


- Cord blood transplants can treat cancers and other diseases in children and adults. The U.S. Food and Drug Administration (FDA) requires cord blood to be collected and stored under certain safety standards. However, most available cord blood units were collected before the FDA set these standards. These units may not meet FDA standards, but they do meet similar standards set and followed by the National Marrow Donor Program (NMDP). Cord blood units that do not meet the new FDA standards may be used for transplants only as part of a research study. Doctors want to allow people who need transplants to receive cord blood that meets NMDP standards but may not meet FDA standards.


- To allow selected cord blood units that do not meet current FDA standards to be used for transplant.


- Individuals who need cord blood units for transplant, and who best match cord blood units that are not FDA-licensed.


  • Participants will provide consent to receive cord blood that meets NMDP standards but may not meet FDA standards.
  • Participants will remain on the study for observation for up to 1 year after transplant, or until they withdraw from the study for personal or medical reasons.

Condition Intervention Phase
Myelodysplastic Syndrome (MDS)
Hematologic Neoplasms
Hematologic Diseases
Severe Aplastic Anemia
Procedure: Cord Blood Transplant
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To examine the incidence of neutrophil recovery of greater than or equal to 500/mm (3) after unlicensed CBU transplant.

Secondary Outcome Measures:
  • Assess incidence of graft rejection, transmission of infection, serious infusion reactions.
  • Determine 1 year survival.
  • Assess cumulative incidence of acute GVHD (grades II to IV), (grades III to IV), and incidence of chronic GVHD.

Estimated Enrollment: 500
Study Start Date: February 1, 2012
Estimated Study Completion Date: October 20, 2030
Estimated Primary Completion Date: October 20, 2030 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment
  • Signed informed consent (and signed assent, if applicable) obtained prior to study enrollment
  • Pediatric and adult patients of any age


  • Patients who are receiving only licensed CBUs
  • Cord blood transplant recipients at international transplant centers
  • Patients who are enrolled on another IND protocol to access the unlicensed CBU(s)
  • Patients whose selected unlicensed CBU(s) will be more than minimally manipulated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01553461

Contact: Richard W Childs, M.D. (301) 451-7128

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Richard W Childs, M.D. National Heart, Lung, and Blood Institute (NHLBI)
  More Information

Additional Information:
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI) Identifier: NCT01553461     History of Changes
Other Study ID Numbers: 120064
Study First Received: March 13, 2012
Last Updated: May 12, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):
Umbilical Cord Blood
Graft Rejection
Graft Versus Host Disease

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Anemia, Aplastic
Hematologic Diseases
Hematologic Neoplasms
Bone Marrow Diseases
Precancerous Conditions
Neoplasms by Site processed this record on May 25, 2017